References
1. T. Lindahl, D.E. Barnes, Repair of Endogenous DNA Damage, Cold Spring Harb. Symp. Quant. Biol. 65 (2000) 127–134. doi:10.1101/sqb.2000.65.127
2. J.F. Ward, DNA Damage Produced by Ionizing Radiation in Mammalian Cells: Identities, Mechanisms of Formation, and Reparability, Prog. Nucleic Acid Res. Mol. Biol. 35 (1988) 95–125. doi:10.1016/S0079-6603(08)60611-X.
3. P. Workman, Drugging the cancer kinome: Progress and challenges in developing personalized molecular cancer therapeutics, in: Cold Spring Harb. Symp. Quant. Biol., 2005: pp. 499–515. doi:10.1101/sqb.2005.70.020.
4. E.D.G. Fleuren, L. Zhang, J. Wu, R.J. Daly, The kinome “at large” in cancer, Nat. Rev. Cancer. 16 (2016) 83–98. doi:10.1038/nrc.2015.18.
5. M. Owusu, P. Bannauer, J. Ferreira da Silva, T.P. Mourikis, A. Jones, P. Májek, M. Caldera, M. Wiedner, C.-H. Lardeau, A.C. Mueller, J. Menche, S. Kubicek, F.D. Ciccarelli, J.I. Loizou, Mapping the Human Kinome in Response to DNA Damage., Cell Rep. 26 (2019) 555-563.e6. doi:10.1016/j.celrep.2018.12.087.
6. A.N. Blackford, S.P. Jackson, ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response, Mol. Cell. 66 (2017) 801–817. doi:10.1016/j.molcel.2017.05.015.
7. A. Maréchal, L. Zou, DNA damage sensing by the ATM and ATR kinases., Cold Spring Harb. Perspect. Biol. 5 (2013). doi:10.1101/cshperspect.a012716.
8. C.A. Lovejoy, D. Cortez, Common mechanisms of PIKK regulation, DNA Repair (Amst). 8 (2009) 1004–1008. doi:10.1016/j.dnarep.2009.04.006.
9. G.C.M. Smith, S.P. Jackson, The DNA-dependent protein kinase, Genes Dev. 13 (1999) 916–934. doi:10.1101/gad.13.8.916
10. R. Bosotti, A. Isacchi, E.L.L. Sonnhammer, FAT: A novel domain in PIK-related kinases, Trends Biochem. Sci. 25 (2000) 225–227. doi:10.1016/S0968-0004(00)01563-2.
11. J. Perry, N. Kleckner, The ATRs, ATMs, and TORs are giant HEAT repeat proteins, Cell. 112 (2003) 151–155. doi:10.1016/S0092-8674(03)00033-3.
12. S.T. Kim, D.S. Lim, C.E. Canman, M.B. Kastan, Substrate specificities and identification of putative substrates of ATM kinase family members, J. Biol. Chem. 274 (1999) 37538–37543. doi:10.1074/jbc.274.53.37538.
13. S.P. Lees-Miller, C.W. Anderson, The human double-stranded DNA-activated protein kinase phosphorylates the 90-kDa heat-shock protein, hsp90?? at two NH2-terminal threonine residues, J. Biol. Chem. 264 (1989) 17275–17280.
14. . O’Neill, A.J. Dwyer, Y. Ziv, D.W. Chan, S.P. Lees-Miller, R.H. Abraham, J.H. Lai, D. Hill, Y. Shiloh, L.C. Cantley, G.A. Rathbun, Utilization of oriented peptide libraries to identify substrate motifs selected by ATM, J. Biol. Chem. 275 (2000) 22719–22727. doi:10.1074/jbc.M001002200.
15. N. Uematsu, E. Weterings, K.I. Yano, K. Morotomi-Yano, B. Jakob, G. Taucher-Scholz, P.O. Mari, D.C. Van Gent, B.P.C. Chen, D.J. Chen, Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks, J. Cell Biol. 177 (2007) 219–229. doi:10.1083/jcb.200608077.
16. C.J. Bakkenist, M.B. Kastan, DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation., Nature. 421 (2003) 499–506. doi:10.1038/nature01368.
17. S. Liu, B. Shiotani, M. Lahiri, A. Maréchal, A. Tse, C.C.Y. Leung, J.N.M. Glover, X.H. Yang, L. Zou, ATR Autophosphorylation as a Molecular Switch for Checkpoint Activation, Mol. Cell. 43 (2011) 192–202. doi:10.1016/j.molcel.2011.06.019.
18. B.K. Singleton, M.I. Torres-Arzayus, S.T. Rottinghaus, G.E. Taccioli, P.A. Jeggo, The C Terminus of Ku80 Activates the DNA-Dependent Protein Kinase Catalytic Subunit, Mol. Cell. Biol. 19 (2015) 3267–3277. doi:10.1128/mcb.19.5.3267
19. S. Difilippantonio, A. Celeste, O. Fernandez-Capetillo, H.T. Chen, B.R. San Martin, F. Van Laethem, Y.P. Yang, G. V. Petukhova, M. Eckhaus, L. Feigenbaum, K. Manova, M. Kruhlak, R.D. Camerini-Otero, S. Sharan, M. Nussenzweig, A. Nussenzweig, Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models, Nat. Cell Biol. 7 (2005) 675–685. doi:10.1038/ncb1270.
20. H.L. Ball, D. Cortez, ATRIP oligomerization is required for ATR-dependent checkpoint signaling, J. Biol. Chem. 280 (2005) 31390–31396. doi:10.1074/jbc.M504961200
21. C. Doil, N. Mailand, S. Bekker-Jensen, P. Menard, D.H. Larsen, R. Pepperkok, J. Ellenberg, S. Panier, D. Durocher, J. Bartek, J. Lukas, C. Lukas, RNF168 Binds and Amplifies Ubiquitin Conjugates on Damaged Chromosomes to Allow Accumulation of Repair Proteins, Cell. 136 (2009) 435–446. doi:10.1016/j.cell.2008.12.041.
22. M.K. Ayrapetov, O. Gursoy-Yuzugullu, C. Xu, Y. Xu, B.D. Price, DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin, Proc. Natl. Acad. Sci. 111 (2014) 9169–9174. doi:10.1073/pnas.1403565111.
23. B. Qin, J. Yu, S. Nowsheen, M. Wang, X. Tu, T. Liu, H. Li, L. Wang, Z. Lou, UFL1 promotes histone H4 ufmylation and ATM activation, Nat. Commun. 10 (2019). doi:10.1038/s41467-019-09175-0.
24. K. Tatsumi, Y.S. Sou, N. Tada, E. Nakamura, S.I. Iemura, T. Natsume, S.H. Kang, C.H. Chung, M. Kasahara, E. Kominami, M. Yamamoto, K. Tanaka, M. Komatsu, A novel type of E3 ligase for the Ufm1 conjugation system, J. Biol. Chem. 285 (2010) 5417–5427. doi:10.1074/jbc.M109.036814.
25. Z. Wang, Y. Gong, B. Peng, R. Shi, D. Fan, H. Zhao, M. Zhu, H. Zhang, Z. Lou, J. Zhou, W.-G. Zhu, Y.-S. Cong, X. Xu, MRE11 UFMylation promotes ATM activation, Nucleic Acids Res. (2019). doi:10.1093/nar/gkz110.
26. G.H. Ha, J.H. Ji, S. Chae, J. Park, S. Kim, J.K. Lee, Y. Kim, S. Min, J.M. Park, T.H. Kang, H. Lee, H. Cho, C.W. Lee, Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks, Nat. Commun. 10 (2019). doi:10.1038/s41467-019-09641-9.
27. P.-O. Mari, B.I. Florea, S.P. Persengiev, N.S. Verkaik, H.T. Bruggenwirth, M. Modesti, G. Giglia-Mari, K. Bezstarosti, J.A.A. Demmers, T.M. Luider, A.B. Houtsmuller, D.C. van Gent, Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4, Proc. Natl. Acad. Sci. 103 (2006) 18597–18602. doi:10.1073/pnas.0609061103.
28. J.R. Walker, R.A. Corpina, J. Goldberg, Structure of the Ku heterodimer bound to dna and its implications for double-strand break repair, Nature. 412 (2001) 607–614. doi:10.1038/35088000.
29. A.A. Goodarzi, Y. Yu, E. Riballo, P. Douglas, S.A. Walker, R. Ye, C. Härer, C. Marchetti, N. Morrice, P.A. Jeggo, S.P. Lees-Miller, DNA-PK autophosphorylation facilitates Artemis endonuclease activity, EMBO J. 25 (2006) 3880–3889. doi:10.1038/sj.emboj.7601255.
30. S. Mohapatra, M. Kawahara, I.S. Khan, S.M. Yannone, L.F. Povirk, Restoration of G1 chemo/radioresistance and double-strand-break repair proficiency by wild-type but not endonuclease-deficient Artemis, Nucleic Acids Res. 39 (2011) 6500–6510. doi:10.1093/nar/gkr257.
31. Y. Zhou, J.H. Lee, W. Jiang, J.L. Crowe, S. Zha, T.T. Paull, Regulation of the DNA Damage Response by DNA-PKcs Inhibitory Phosphorylation of ATM, Mol. Cell. 65 (2017) 91–104. doi:10.1016/j.molcel.2016.11.004.
32. L. Zou, S.J. Elledge, Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes, Science (80-. ). 300 (2003) 1542–1548. doi:10.1126/science.1083430.
33. J. Lee, A. Kumagai, W.G. Dunphy, The Rad9-Hus1-Rad1 checkpoint clamp regulates interaction of TopBP1 with ATR, J. Biol. Chem. 282 (2007) 28036–28044. doi:10.1074/jbc.M704635200
34. S. Delacroix, J.M. Wagner, M. Kobayashi, K.I. Yamamoto, L.M. Karnitz, The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via TopBP1, Genes Dev. 21 (2007) 1472–1477. doi:10.1101/gad.1547007.
35. P. Haahr, S. Hoffmann, M.A.X. Tollenaere, T. Ho, L.I. Toledo, M. Mann, S. Bekker-Jensen, M. Räschle, N. Mailand, Activation of the ATR kinase by the RPA-binding protein ETAA1, Nat. Cell Biol. 18 (2016) 1196–1207. doi:10.1038/ncb3422
36. Y.C. Lee, Q. Zhou, J. Chen, J. Yuan, RPA-Binding Protein ETAA1 Is an ATR Activator Involved in DNA Replication Stress Response, Curr. Biol. 26 (2016) 3257–3268. doi:10.1016/j.cub.2016.10.030.
37. S. Feng, Y. Zhao, Y. Xu, S. Ning, W. Huo, M. Hou, G. Gao, J. Ji, R. Guo, D. Xu, Ewing tumor-associated antigen 1 interacts with replication protein A to promote restart of stalled replication forks, J. Biol. Chem. 291 (2016) 21956–21962. doi:10.1074/jbc.C116.747758.
38. J. Bartek, J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer, Cancer Cell. 3 (2003) 421–429. doi:10.1016/S1535-6108(03)00110-7.
39. S. Banin, L. Moyal, S.Y. Shieh, Y. Taya, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, Y. Ziv, Enhanced phosphorylation of p53 by ATM in response to DNA damage, Science (80-. ). 281 (1998) 1674–1677. doi:10.1126/science.281.5383.1674.
40. N.D. Lakin, B.C. Hann, S.P. Jackson, The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53, Oncogene. 18 (1999) 3989–3995. doi:10.1038/sj.onc.1202973.
41. J.Y. Ahn, J.K. Schwarz, H. Piwnica-Worms, C.E. Canman, Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation, Cancer Res. 60 (2000) 5934–5936.
42. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al, DNA damage-induced activation of p53 by the checkpoint kinase Chk2., Science (80-. ). 287 (2000) 1824–7.
43. J. Falck, N. Mailand, R.G. Syljuåsen, J. Bartek, J. Lukas, The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis, Nature. 410 (2001) 842–847. doi:10.1038/35071124.
44. Q. Liu, S. Guntuku, X.S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, L.A. Donehower, S.J. Elledge, Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint, Genes Dev. 14 (2000) 1448–1459.
45. A.L. Brown, C.-H. Lee, J.K. Schwarz, N. Mitiku, H. Piwnica-Worms, J.H. Chung, A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage, Proc. Natl. Acad. Sci. 96 (2002) 3745–3750. doi:10.1073/pnas.96.7.3745.
46. I. Dauth, J. Krüger, T.G. Hofmann, Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM, Cancer Res. 67 (2007) 2274–2279. doi:10.1158/0008-5472.CAN-06-2884.
47. N. Reuven, J. Adler, Z. Porat, T. Polonio-Vallon, T.G. Hofmann, Y. Shaul, The tyrosine kinase c-Abl promotes HIPK2 accumulation and activation in response to DNA damage, J. Biol. Chem. 290 (2015) jbc.M114.628982. doi:10.1074/jbc.M114.628982.
48. Y. Chen, C.F. Chen, D.J. Riley, P.L. Chen, Nek1 kinase functions in DNA damage response and checkpoint control through a pathway independent of ATM and ATR, Cell Cycle. 10 (2011) 655–663. doi:10.4161/cc.10.4.14814.
49. R. Polci, A. Peng, P.L. Chen, D.J. Riley, Y. Chen, NIMA-related protein kinase 1 is involved early in the ionizing radiation-induced DNA damage response, Cancer Res. 64 (2004) 8800–8803. doi:10.1158/0008-5472.CAN-04-2243.
50. X. Chen, H. Zhu, M. Yuan, J. Fu, Y. Zhou, L. Ma, G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis, J. Biol. Chem. 285 (2010) 12823–12830. doi:10.1074/jbc.M109.094243
51. S. Zirkin, A. Davidovich, J. Don, The PIM-2 kinase is an essential component of the ultraviolet damage response that acts upstream to E2F-1 and ATM, J. Biol. Chem. 288 (2013) 21770–21783. doi:10.1074/jbc.M113.458851.
52. J. Ramachandran, L. Santo, K.T. Siu, C. Panaroni, N. Raje, Pim2 is important for regulating DNA damage response in multiple myeloma cells, Blood Cancer J. 6 (2016) e462. doi:10.1038/bcj.2016.73.
53. L. Herhaus, A.B. Perez-Oliva, G. Cozza, R. Gourlay, S. Weidlich, D.G. Campbell, L.A. Pinna, G.P. Sapkota, Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization, Sci. Signal. 8 (2015). doi:10.1126/scisignal.aaa0441.
54. J.R. Chapman, S.P. Jackson, Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage, EMBO Rep. 9 (2008) 795–801. doi:10.1038/embor.2008.103.
55. J. Roig, J.A. Traugh, p21-activated protein kinase γ-PAK is activated by ionizing radiation and other DNA-damaging agents. Similarities and differences to α-PAK, J. Biol. Chem. 274 (1999) 31119–31122. doi:10.1074/jbc.274.44.31119.
56. Y. Fang, T. Liu, X. Wang, Y.M. Yang, H. Deng, J. Kunicki, F. Traganos, Z. Darzynkiewicz, L. Lu, W. Dai, BubR1 is involved in regulation of DNA damage responses, Oncogene. 25 (2006) 3598–3605. doi:10.1038/sj.onc.1209392.
57. O. Marin, F. Meggio, S. Sarno, L. Cesaro, M.A. Pagano, L.A. Pinna, Tyrosine Versus Serine/Threonine Phosphorylation by Protein Kinase Casein Kinase-2 , J. Biol. Chem. 274 (2002) 29260–29265. doi:10.1074/jbc.274.41.29260.
58. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the human genome, Science (80-. ). 298 (2002) 1912–1934. doi:10.1126/science.1075762.
59. S.R. Hubbard, J.H. Till, Protein Tyrosine Kinase Structure and Function, Annu. Rev. Biochem. 69 (2000) 373–398. doi:10.1146/annurev.biochem.69.1.373.
60. K. Dittmann, C. Mayer, R. Kehlbach, H.P. Rodemann, Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK, Mol. Cancer. 7 (2008). doi:10.1186/1476-4598-7-69.
61. Z. Zhou, H. Lu, S. Zhu, A. Gomaa, Z. Chen, J. Yan, K. Washington, W. El-Rifai, C. Dang, D. Peng, Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage, J. Exp. Clin. Cancer Res. 38 (2019). doi:10.1186/s13046-018-1021-y.
62. A.M. Ohm, T. Affandi, M.E. Reyland, EGF receptor and PKC kinase activate DNA damage–induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases, J. Biol. Chem. 294 (2019) 4488–4497. doi:10.1074/jbc.RA118.006944.
63. S. Nowsheen, T. Cooper, J.A. Stanley, E.S. Yang, Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells, PLoS One. 7 (2012). doi:10.1371/journal.pone.0046614.
64. H.J. Lee, L. Lan, G. Peng, W.C. Chang, M.C. Hsu, Y.N. Wang, C.C. Cheng, L. Wei, S. Nakajima, S.S. Chang, H.W. Liao, C.H. Chen, M. Lavin, K.K. Ang, S.Y. Lin, M.C. Hung, Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response, Cell Res. 25 (2015) 225–236. doi:10.1038/cr.2015.8.
65. J. Trojanek, T. Ho, L. Del Valle, M. Nowicki, J.Y. Wang, A. Lassak, F. Peruzzi, K. Khalili, T. Skorski, K. Reiss, Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination., Mol. Cell. Biol. 23 (2003) 7510–24. http://www.ncbi.nlm.nih.gov/pubmed/14559999%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC207618.
66. S. Yang, J. Chintapalli, L. Sodagum, S. Baskin, A. Malhotra, K. Reiss, L.G. Meggs, Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination, Am. J. Physiol. Physiol. 289 (2005) F1144–F1152. doi:10.1152/ajprenal.00094.2005.
67. M.G. Kemp, D.F. Spandau, R. Simman, J.B. Travers, Insulin-like Growth Factor 1 Receptor Signaling Is Required for Optimal ATR-CHK1 Kinase Signaling in Ultraviolet B (UVB)-irradiated Human Keratinocytes., J. Biol. Chem. 292 (2017) 1231–1239. doi:10.1074/jbc.M116.765883.
68. M. Bibel, Y.A. Barde, Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system, Genes Dev. 14 (2000) 2919–2937. doi:10.1101/gad.841400.
69. J.H. Schulte, S. Kuhfittig-Kulle, L. Klein-Hitpass, A. Schramm, D.S.F. Biard, P. Pfeiffer, A. Eggert, Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells, DNA Repair (Amst). 7 (2008) 1757–1764. doi:10.1016/j.dnarep.2008.07.004.
70. S. Jin, S. Kharbanda, B. Mayer, D. Kufe, D.T. Weaver, Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit, J. Biol. Chem. 272 (1997) 24763–24766. doi:10.1074/jbc.272.40.24763.
71. K. Burger, M. Schlackow, M. Gullerova, Tyrosine kinase c-Abl couples RNA polymerase II transcription to DNA double-strand breaks, Nucleic Acids Res. 47 (2019) 3467–3484. doi:10.1093/nar/gkz024.
72. Y. Fukumoto, M. Morii, T. Miura, S. Kubota, K. Ishibashi, T. Honda, A. Okamoto, N. Yamaguchi, A. Iwama, Y. Nakayama, N. Yamaguchi, Src family kinases promote silencing of atr-chk1 signaling in termination of DNA damage checkpoint, J. Biol. Chem. 289 (2014) 12313–12329. doi:10.1074/jbc.M113.533752.
73. S. Kumar, P. Pandey, A. Bharti, S. Jin, R. Weichselbaum, D. Weaver, D. Kufe, S. Kharbanda, Regulation of DNA-dependent protein kinase by the Lyn tyrosine kinase, J. Biol. Chem. 273 (1998) 25654–25658. doi:10.1074/jbc.273.40.25654.
74. J.-H. Ji, S. Min, S. Chae, G.-H. Ha, Y. Kim, Y.-J. Park, C.-W. Lee, H. Cho, De novo phosphorylation of H2AX by WSTF regulates transcription-coupled homologous recombination repair., Nucleic Acids Res. (2019). doi:10.1093/nar/gkz309.
75. W. Becker, Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control, Cell Cycle. 11 (2012) 3389–3394. doi:10.4161/cc.21404.
76. N. Taira, K. Nihira, T. Yamaguchi, Y. Miki, K. Yoshida, DYRK2 Is Targeted to the Nucleus and Controls p53 via Ser46 Phosphorylation in the Apoptotic Response to DNA Damage, Mol. Cell. 25 (2007) 725–738. doi:10.1016/j.molcel.2007.02.007.
77. L. Litovchick, L.A. Florens, S.K. Swanson, M.P. Washburn, J.A. Decaprio, DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly, Genes Dev. 25 (2011) 801–813. doi:10.1101/gad.2034211.
78. N. Taira, H. Yamamoto, T. Yamaguchi, Y. Miki, K. Yoshida, ATM augments nuclear stabilization of DYRK2 by inhibiting MDM2 in the apoptotic response to DNA damage, J. Biol. Chem. 285 (2010) 4909–4919. doi:10.1074/jbc.M109.042341.
79. V. R. Menon, V. Ananthapadmanabhan, S. Swanson, S. Saini, F. Sesay, V. Yakovlev, L. Florens, J.A. DeCaprio, M. P. Washburn, M. Dozmorov, L. Litovchick, DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169, Cell Cycle. 18 (2019) 531–551. doi:10.1080/15384101.2019.1577525.
80. J. Roewenstrunk, C. Di Vona, J. Chen, E. Borras, C. Dong, K. Arató, E. Sabidó, M.S.Y. Huen, S. de la Luna, A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response, Sci. Rep. 9 (2019). doi:10.1038/s41598-019-42445-x.
81. S.E. Guard, Z.C. Poss, C.C. Ebmeier, M. Pagratis, H. Simpson, D.J. Taatjes, W.M. Old, The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair, Sci. Rep. 9 (2019) 6539. doi:10.1038/s41598-019-42990-5.
82. F.F. Hsu, T.Y. Lin, J.Y. Chen, S.Y. Shieh, P53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control, Oncogene. 29 (2010) 2864–2876. doi:10.1038/onc.2010.40.
83. G.B. Mills, R. Schmandt, M. McGill, A. Amendola, M. Hill, K. Jacobs, C. May, A.M. Rodricks, S. Campbell, D. Hogg, Expression of TTK, a novel human protein kinase, is associated with cell proliferation, J. Biol. Chem. 267 (1992) 16000–16006.
84. J.H. Wei, Y.F. Chou, Y.H. Ou, Y.H. Yeh, S.W. Tyan, T.P. Sun, C.Y. Shen, S.Y. Shieh, TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68, J. Biol. Chem. 280 (2005) 7748–7757. doi:10.1074/jbc.M410152200.
85. Z.C. Yu, Y.F. Huang, S.Y. Shieh, Requirement for human mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation, Nucleic Acids Res. 44 (2016) 1133–1150. doi:10.1093/nar/gkv1173.
86. D. Hernández-Flórez, L. Valor, Protein-kinase Inhibitors: A New Treatment Pathway for Autoimmune and Inflammatory Diseases?, Reumatol. Clínica (English Ed. (2016). doi:10.1016/j.reumae.2015.06.003.
87. J.E. Dancey, H.X. Chen, Strategies for optimizing combinations of molecularly targeted anticancer agents, Nat. Rev. Drug Discov. (2006). doi:10.1038/nrd2089.
88. A. Minchom, C. Aversa, J. Lopez, Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies, Ther. Adv. Med. Oncol. 10 (2018). doi:10.1177/1758835918786658.
89. D. Velic, A.M. Couturier, M.T. Ferreira, A. Rodrigue, G.G. Poirier, F. Fleury, J.Y. Masson, DNA damage signalling and repair inhibitors: The long-sought-after achilles’ heel of cancer, Biomolecules. 5 (2015) 3204–3259. doi:10.3390/biom5043204.
90. M.E.M. Noble, J.A. Endicott, L.N. Johnson, Protein Kinase Inhibitors: Insights into Drug Design from Structure, Science (80-. ). (2004). doi:10.1126/science.1095920.
91. K. Takeuchi, F. Ito, Receptor Tyrosine Kinases and Targeted Cancer Therapeutics, Biol. Pharm. Bull. (2011). doi:10.1248/bpb.34.1774.
92. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, R.A. Sharma, DNA repair pathways as targets for cancer therapy, Nat. Rev. Cancer. (2008). doi:10.1038/nrc2342.
93. D. Singh, B. Attri, R. Gill, J. Bariwal, Review On EGFR Inhibitors: Critical Updates, Mini-Reviews Med. Chem. 16 (2016) 1–1. doi:10.2174/1389557516666160804162457.
94. C.M. Lovly, N.T. McDonald, H. Chen, S. Ortiz-Cuaran, L.C. Heukamp, Y. Yan, A. Florin, L. Ozretić, D. Lim, L. Wang, Z. Chen, X. Chen, P. Lu, P.K. Paik, R. Shen, H. Jin, R. Buettner, S. Ansén, S. Perner, M. Brockmann, M. Bos, J. Wolf, M. Gardizi, G.M. Wright, B. Solomon, P.A. Russell, T.M. Rogers, Y. Suehara, M. Red-Brewer, R. Tieu, E. De Stanchina, Q. Wang, Z. Zhao, D.H. Johnson, L. Horn, K.K. Wong, R.K. Thomas, M. Ladanyi, W. Pao, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer, Nat. Med. 20 (2014) 1027–1034. doi:10.1038/nm.3667.
95. A. Drilon, T.W. Laetsch, S. Kummar, S.G. DuBois, U.N. Lassen, G.D. Demetri, M. Nathenson, R.C. Doebele, A.F. Farago, A.S. Pappo, B. Turpin, A. Dowlati, M.S. Brose, L. Mascarenhas, N. Federman, J. Berlin, W.S. El-Deiry, C. Baik, J. Deeken, V. Boni, R. Nagasubramanian, M. Taylor, E.R. Rudzinski, F. Meric-Bernstam, D.P.S. Sohal, P.C. Ma, L.E. Raez, J.F. Hechtman, R. Benayed, M. Ladanyi, B.B. Tuch, K. Ebata, S. Cruickshank, N.C. Ku, M.C. Cox, D.S. Hawkins, D.S. Hong, D.M. Hyman, Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , N. Engl. J. Med. 378 (2018) 731–739. doi:10.1056/nejmoa1714448.
96. M.D. Moen, K. McKeage, G.L. Plosker, M.A.A. Siddiqui, Imatinib: A review of its use in chronic myeloid leukaemia, Drugs. 67 (2007) 299–320. doi:10.2165/00003495-200767020-00010.
97. L.N. Puls, M. Eadens, W. Messersmith, Current Status of Src Inhibitors in Solid Tumor Malignancies, Oncologist. 16 (2011) 566–578. doi:10.1634/theoncologist.2010-0408.
98. H.-J. Nam, S.-A. Im, D.-Y. Oh, P. Elvin, H.-P. Kim, Y.-K. Yoon, A. Min, S.-H. Song, S.-W. Han, T.-Y. Kim, Y.-J. Bang, Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer., Mol. Cancer Ther. 12 (2013) 16–26. doi:10.1158/1535-7163.MCT-12-0109.
99. N. Göckler, G. Jofre, C. Papadopoulos, U. Soppa, F.J. Tejedor, W. Becker, Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation, FEBS J. 276 (2009) 6324–6337. doi:10.1111/j.1742-4658.2009.07346.x.
100. F. Manetti, Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials, Eur. J. Med. Chem. 155 (2018) 445–458. doi:10.1016/j.ejmech.2018.06.016.